COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Jaguar Health plans to utilize AI platforms to enhance the development and commercialization of crofelemer for intestinal failure treatment, targeting ultrarare pediatric disorder MVID -
-
-
COMMUNIQUÉ DE PRESSE
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Jaguar Health, Inc. announces participation details for upcoming webcast on April 10, 2026. Learn about their novel prescription drugs derived from plants for GI diseases -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. completes study on crofelemer for cancer therapy-induced diarrhea in dogs. Results expected to complement positive outcomes. Company plans to file effectiveness study by Q2 2026
